Ichnos Glenmark Innovation

What exactly are multispecific antibodies – or multispecifics™? Learn more about the advantages of multispecifics at https://bit.ly/3SHzDAh #biotechnology #biologics #antibodies #partnering #biopharma

Highlights of our most recent quarter include an oral presentation on our novel, clinical-stage multispecific™ asset ISB 2001 at AACR in April 2024. Read more about how we continue to advance our innovations in oncology in our quarterly update: https://bit.ly/3YIa0D3 #Biotechnology #CancerResearch #AACR2024

Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals, discusses the formation of IGI and Glenmark’s investment in innovative medicines in a recent article in India-based Business Today magazine. Read the full story: https://bit.ly/4fB9JYA #Glenmark #healthcare #biotechnology #innovation

Our BEAT® platform enables deep exploration of the bi/multispecific design space to optimize drug candidates and unlock new biology including T-cell, NK cells, and macrophage engagers. We leveraged this proprietary technology to create both of our clinical-stage assets being studied in multiple myeloma. Interested in learning more about collaborating with IGI within oncology, autoimmune diseases or beyond? Check out https://bit.ly/3SzfLiG. #biotechnology #biopharma #collaboration

We’re excited to share that we have expanded the clinical study of ISB 2001, our first-in-class trispecific antibody for the potential treatment of multiple myeloma, and dosed the first participant in India. This clinical site initiation leverages the regulatory expertise in India of our alliance partner, Glenmark Pharmaceuticals. This milestone follows the launch of our clinical study in Australia, IND clearance from the U.S. FDA, and orphan drug designation last year. Clinical study details available at https://bit.ly/4cSYitD (NCT05862012). #ClinicalTrials #ClinicalResearch #Cancer #Hematology

IGI is pleased to share that IGI scientists have contributed two chapters to the newly published book, "Recombinant Protein Expression in Mammalian Cells," part of the Springer Protocols book series. This comprehensive guide delves into the cutting-edge techniques and methodologies in the field of protein expression. The two chapters IGI contributed provide valuable and practical insights for the expression of bi- and multispecific antibodies. The first chapter describes an optimized methodology to express and purify basic bispecific antibodies using the BEAT® interface. This technique allows for the generation of antibodies with very high levels of heterodimer product and includes a built-in purification strategy to remove undesired impurities. The second chapter details protocols for the use of cellular display technology to streamline the identification and selection of high-producing cell lines. IGI is grateful for the opportunity to contribute to this influential work together with leading experts in the field. If you are interested in the latest advancements in recombinant protein expression, we highly recommend checking out this book! https://bit.ly/3LqhRNM #molecularbiology #antibodies #biotechnology #drugdevelopment Springer Nature Group

ISB 2001 is our first-in-class T cell-engaging trispecific antibody in clinical development for the potential treatment of multiple myeloma. This novel multispecific™ simultaneously targets BCMA and CD38 on myeloma cells and CD3 to engage T cells. Watch this video to learn how ISB 2001’s unique design induces more potent killing of myeloma cells than mono-targeted therapies: https://bit.ly/3L2PSmY #Myeloma #CancerResearch #Biotechnology #Innovation

Multiple myeloma is often unresponsive to standard monoclonal antibody treatments due to multiple mechanisms that allow for immune evasion. ISB 1442, a CD38 x CD47 bispecific antibody, is designed to counteract these evasion mechanisms. Find out how ISB 1442 works in our new MOA video: https://bit.ly/4esleky #Cancer #Myeloma #Biotech

With the formation of IGI earlier this year, our leadership team now includes the heads of our global centers of scientific excellence in Lausanne, Switzerland and Mumbai, India. Our leaders fully believe in the power of collaboration to drive innovation in oncology forward. More about our leadership team at https://bit.ly/3KGo87y #Biotechnology #CancerResearch

Connect with the Glenmark and Ichnos Glenmark Innovation Business Development teams at the BIO International Convention and discover how we are advancing innovation in the pharmaceutical industry. Meet Marco Cerato, Executive Vice President and Global Head - Business Development, Alliance, Portfolio, Branding and Medical Affairs, Dr. Bianca Ahrens, Senior Director and Head - Global Business Development Innovation, and Sebastien Chenuet, Vice President and Head of Business Development and Investor Relations – Ichnos Glenmark Innovation, at the event. Marco highlights that, “Glenmark is dedicated to strengthening its portfolio in Oncology, Respiratory, and Dermatology and we believe that partnership are key to our success. Bianca, Sebastien and I are excited to connect with you in San Diego.” Let's shape #ANewWayForANewWorld together! #Glenmark #Event #BIO2024 #HealthcareInnovation